Fragile X syndrome: overview, genetics, features, diagnosis, and management

Genetic basis and mechanism

The condition results from an alteration in the FMR1 gene, typically an expansion of a repeated trinucleotide sequence. When this expansion reaches a certain size it interferes with normal gene expression and reduces production of the fragile X mental retardation protein (FMRP), which is important for brain development and synaptic function. Individuals with smaller expansions — called premutations — can be symptom-free or can develop related conditions later in life. For technical summaries consult molecular genetics references.

Typical characteristics

Clinical features cover cognitive, behavioral and physical domains. Cognitive effects range from learning difficulties to intellectual disability. Many affected individuals show autistic-like behaviors, language delay, anxiety, hyperactivity and sensory sensitivity. Characteristic physical features, more apparent in adolescence or adulthood, can include a long face, large ears and, in males after puberty, enlarged testes (macroorchidism). Female carriers may show subtler signs due to X-chromosome inactivation. For clinical descriptions see clinical overviews.

Diagnosis and testing

Diagnosis is confirmed by a DNA test that measures the FMR1 repeat size and methylation status. Testing is used for symptomatic individuals, for family members when a case is identified, and in some prenatal contexts. Newborn screening is not universally implemented, so diagnosis often follows developmental concerns. Genetic counseling is advised to explain inheritance, recurrence risks and reproductive options. Practical guidance is available at testing and counseling.

Management, prognosis and public health

There is no cure that reverses the underlying gene change; management focuses on therapies to improve function and quality of life. Educational supports, speech and language therapy, occupational therapy and behavioral interventions are central. Medications may be prescribed to address anxiety, attention problems, or seizures when present. Lifelong follow-up, family support and genetic counseling help families plan care. Research into targeted treatments and clinical trials continues; see research summaries.

Notable distinctions: the term "fragile X" originally referred to a fragile appearance of a site on the X chromosome seen in some lab tests. Today the condition is defined and detected at the DNA level. Carriers of premutations should be aware of later-onset related syndromes and reproductive effects distinct from classic fragile X syndrome. Ongoing research aims to improve therapies and early identification.